Page 1254 - Veterinary Toxicology, Basic and Clinical Principles, 3rd Edition

Index 1185

VetBooks.ir Loratadine, 376, 376t M (M. fulvius barbouri) function, 829
physiology, 285 286
Low CN-containing cultivars, 939
M. fulvius barbouri. See Florida coral snake
spermatogenesis, 283 285
Low larkspur (Delphinium bicolor), 846 848,
846f
and mechanisms of action, 299 303
Low plasma calcium, 424 M. fulvius fulvius. See Eastern coral snake (M. toxicants affecting function, 299 303
fulvius fulvius)
Lowest observed adverse effect level M. fulvius tenere. See Texas coral snake (M. Mallards (Anas platyrhynchos), 592
(LOAEL), 27, 118 119 fulvius tenere) Malonylglucoside, 819
Loxoscelism, 782 M. musculus. See Common mice (M. Mammalia, 798 799
LPS. See Lipopolysaccharide (LPS) musculus); House mice (M. musculus) Mammalian
LSA. See Lysergic acid amide (LSA) 4MA. See 4-Methylaminorex (4MA) fipronil, mammalian systems, 535
LSD. See Lysergic acid diethylamide (LSD) mAChR. See Muscarinic ACh receptor kidneys, 259
LTB4, 366 (mAChR) placentation, 292
LTGU. See Laboratory of Toxicology of Ghent Macrocyclic lactone endectocides (MLs), sodium channels, 516
University (LTGU) 539 541 Mammals, 594 595
LTP. See Long-term potentiation (LTP) endectocides, 539 diagnosis, 595
LTs. See Leukotrienes (LTs) abamectin, 540f clinical signs, 595 596
Lubricant laxatives, 379, 907 doramectin, 540f coagulopathy, 596 597
Lu ¨H-6. See Obidoxime dichloride eprinomectin, 540f humans, 594
Lung mechanism of action, 543 544 pediatric vs. adult exposures, 594 595
cancer, 223 milbemycin, 541f Mammary gland, 680
principles in pathogenesis of lung damage moxidectin, 542f Manganese (Mn), 445
oxidant burden, 218 pharmacokinetics/toxicokinetics, 541 543 deficiency, 445
particle size and clearance, 220 221 selamectin, 542f diagnosis, 450
toxic inhalant gases, 218 220 toxicity, 544 547, 545t mechanism of action, 447 449, 448t
toxicology, 215 treatment, 547 548 Mn-induced ROS generation, 448
Lung injury. See also Toxicant-induced liver poisoning, 539 pharmacokinetics/toxicokinetics, 446
injury toxicosis, 544 toxicity, 449 450
acute responses to, 221 222 Macrophages, 243 treatment, 450 451
agents to producing lung injury in animals, Macroscopic pathology Manganism, 445 446
223 224 differential diagnosis, 991 MAO. See Monoamine oxidase (MAO)
chronic responses of, 222 223 edema, 991 MAPK. See Mitogen-activated protein kinase
Lungworm (Dictyocaulus viviparus), hemorrhage, 991 (MAPK)
541 542 hepatic lesions, 991 Margin of exposure (MOE), 119
Lupine-induced crooked calf syndrome, other lesions, 991 Marijuana, 385, 387 390, 896
854 855 Macrovesicular steatosis, 247 cigarettes, 388
Lupines (Lupinus spp.), 312, 837, 852 857, Madder, 232 clinical symptoms, 389
900 mADI. See Microbiological ADI (mADI) mechanism of action, 389
distribution, 852 853 Maduramicin, 720, 1073, 1074f pathology, 390
L. leucophyllus, 852f, 855 Magic mushrooms, 962 toxicity, 388
L. sulphureus, 852f Magnesium hydroxide (Mg(OH) 2 ), 220, 363, toxicokinetics, 388 389
prevention, management, and treatment, 364t, 369 treatment, 389 390
1
856 857 Magnesium ions (Mg2 ), 736 Marinol. See Dronabinol
to toxic or teratogenic, 853t Magnesium oxide (MgO), 220, 321 Marker residue, 95, 126
toxicology, 854 856 Magnesium sulfate, 380, 392 Marketing authorization procedures,
cattle grazing, 855 856 Magnetic resonance imaging, 635 104 106
Lupines, 900 Magnusson-Kligman method, 535 536 centralized or community procedure,
Lupinosis, 900 Maize (Zea mays), 60 104 105
Lupinus spp. See Lupines (Lupinus spp.) Malathion, 495 496, 500f decentralized procedure, 105
Luteinizing hormone (LH), 275, 679, 827, MALDI-TOF/TOF instruments. See Matrix- independent national procedures,
1057 assisted laser desorption ionization/ 105 106
Luteolysis, 289 time-of-flight instruments (MALDI- mutual recognition procedure, 105
Lycoctonine, 230 TOF/TOF instruments) Martes foina. See Stone martens (Martes foina)
Lymphatics, 1007 Male fertility, 276, 300t, 975 Mass analyzers, 1129 1130
Lymphoid necrosis, 370 Male infertility, 298, 829 Mass balance equation, 139
Lymphoplasmacytic nephritis, 1069 Male phenotype development, 294 295 Mass spectral fingerprint, 1130
Lysergic acid amide (LSA), 402 403 Male reproductive Mass spectrometry (MS), 165 166, 598 600,
Lysergic acid diethylamide (LSD), 205 206, anatomy, 281 283 1127 1130
401 403 accessory sex glands, 283 ion sources, 1128 1129
clinical symptoms, 403 excurrent duct system, 283 EI, 1128
mechanism of action, 402 403 external genitalia, 283 ESI, 1128 1129, 1129f
toxicity, 402 testicular structure, 282 283 ICP-MS, 1128
toxicokinetics, 402 effects, 679 680 mass analyzers, 1129 1130
treatment, 403 estrogens as risk factors for male Massive necrosis, 246 247
Lysosomes, 241 242, 727 reproductive tract problems, 813 814 Mast cells, 235